Autoantibodies present in the sera of patients with bullous pemphigoid (BP) bind to the basement membrane zone of normal human skin and commonly recognize two epidermal proteins, the BP240 and BP180 antigens. Two BP antigen cDNA clones from a lambda gtl1 human keratinocyte library have been identified on the basis of reactivity with a BP serum. The fusion protein (FP) produced by one clone immunoadsorbed autoantibodies, which specifically recognized the BP180 antigen, showing no cross-reactivity with BP240 by immunoblot analysis. The FP produced by the second clone immunoadsorbed autoantibodies which specifically reacted with the BP240 epidermal antigen. Northern blot analysis demonstrated that the BP180 and BP240 antigens are encoded by distinct RNA transcripts with lengths of 6.0 and 8.5 kb, respectively. Immunoblot analysis of the BP180 lysogen extract identified a 135-kD FP which was recognized by 7 of 16 BP sera and 7 of 8 herpes gestationis sera. A rabbit antiserum prepared against the lysogenic BP180 FP specifically recognized the BP180 antigen from human epidermal extracts by immunoblotting, labeled the BMZ by indirect immunofluorescence, and bound to human epidermal hemidesmosomes by immuno-electron microscopy. These results indicate that the BP180 antigen recognized by BP and herpes gestationis autoantibodies is a unique hemidesmosomal polypeptide, distinguishable from the BP240 antigen. (J. Clin. Invest. 1990.
membrane zone (BMZ) (1) . BP skin lesions show a clean separation of the epidermis from the dermis through the lamina lucida of the BMZ (2) . In 1967, Jordon et al. (3) , using an immunofluorescence (IF) assay, detected BP autoantibodies bound to the BMZ oflesional skin, as well as circulating in the sera of these patients. Early ultrastructural studies of the tissue-bound autoantibodies showed the immunoreactants to be localized in the lamina lucida of the BMZ (4) . Recent reports have demonstrated that circulating BP autoantibodies bind specifically to the hemidesmosome (5) (6) (7) (8) , an organelle which is thought to be involved in the adherence ofthe epidermal basal cell to the dermis. The relevance of either tissue-bound or circulating autoantibodies with respect to the mechanism of blister formation in BP patients remains unclear.
Several studies have been reported on the characterization of BP antigens. Stanley and collaborators have shown that BP sera bind specifically to a single epidermal polypeptide of 230/240 kD (referred to here as BP240 antigen) by both immunoblotting and immunoprecipitation procedures (9, 10) . Our group and others have found that, in addition to the BP240 antigen, BP sera also recognize lower molecular weight epidermal antigens (11, 12) . One such antigen is the 180-kD protein (referred to here as BPI 80 antigen), which is recognized by -50% of all BP sera and the majority of Herpes Gestationis (HG) sera (13) . HG is an idiopathic subepidermal disease of pregnancy which exhibits several features common to BP, including the presence of anti-BMZ autoantibodies (14) .
Using a BP serum containing autoantibodies against the BP240 antigen, Stanley et al. (15) have recently identified a 2-kb human keratinocyte cDNA that encodes epitope(s) recognized by these autoantibodies. The BP cDNA encoded a fusion protein (FP) which immunoadsorbed BP autoantibodies directed against the BP240 antigen from the respective BP serum. Northern blot analysis has shown that this cDNA hybridizes with a 9-kb keratinocyte transcript.
In this report we describe the characterization of a 1-kb cDNA purified from a keratinocyte cDNA library which encodes an FP recognized by BP and HG autoantibodies against the BPI 80 antigen. A rabbit antiserum prepared against the BP180 cDNA-encoded FP reacted with the BP180 epidermal antigen by immunoblotting and labeled the epidermal hemidesmosome by immuno-electron microscopy (immuno-EM). Northern blot analysis shows hybridization of the BP180 cDNA with a 6.0-kb RNA transcript which is distinct from the 8.5-kb mRNA of the BP240 antigen. This study indicates that the BP240 and BPI 80 antigens are distinct hemidesmosomal proteins.
and normal human donors (NHS) (n = 10) were used in this investigation. The HG sera used in this study were the same as those used in a previous investigation (13) . All BP sera possessed anti-BMZ autoantibodies displaying titers above 1:80 by indirect IF procedures. Using immunoblotting techniques the BP240 antigen was labeled by the majority ofthe BP sera tested, while the BP180 antigen was recognized by half of the BP sera and by all HG sera (results which are consistent with those previously reported) (13) . PV and EPF sera exhibited, by indirect IF, the characteristic epidermal intercellular staining produced by the respective autoantibodies, while the normal human serum (NHS) showed no reactivity with epidermal antigens.
Immunofluorescence and immunoblotting. Reactivity of human sera (or rabbit anti-FP) against the BMZ and ICS of human skin cryosections was investigated by routine indirect IF procedures (5, 13) . Cytospin-fixed trypsin-dissociated human epidermal basal cells were also used to test BP autoantibodies by indirect IF following procedures reported elsewhere (5) . FITC-antihuman IgG and FITC-antirabbit IgG were from Cappel Laboratories (West Chester, PA).
Extraction and electrophoretic separation of epidermal proteins has been described elsewhere (I 1, 13). Briefly, heat-separated human epidermal sheets were extracted by homogenization using a 1% SDS, 0.01 M Tris buffer, pH 7.6 in the presence of 10 mM EDTA, 1 mM PMSF, and 10 gg/ml of each of the following protease inhibitors: leupeptin, antipain, chymostatin, and pepstatin. Reduced SDS-PAGE electrophoresis was carried out using either 7 or 7-15% gradient gels. Similar extraction and electrophoretic procedures were used to solubilize and separate lysogenic extracts containing the putative BP180 FP.
Immunoblotting procedures performed in this study have been described previously by Labib et al. (11) (16) . LacZ-directed expression was induced by first incubating the cultures at 42°C for 3-4 h followed by overlaying an NC filter (previously soaked in 10 mM isopropyl-beta-D-thiogalactopyranoside [IPTGJ) onto the plaques at 37°C for an additional 3-4 h. During this incubation, beta-galactosidase FP is produced by the lytically infected cells and immobilized on the NC paper. After the filters were blocked with 4% BSA in PTX buffer, they were incubated overnight with an appropriate dilution of BP serum. The NC filters were washed thoroughly in GB buffer (50 mM triethanolamine, pH 7.4, 0.5% Triton X-100, 0.1 M NaCI, 2 mM EDTA, and 0.1% SDS) and incubated with 1251-labeled protein A (2 X I05 cpm/ml).
Unbound radiolabeled protein A was removed by washing in GB as above. The immunoreactive clones were detected by autoradiography. To assure plaque purity, repeated rounds of screening of each clone were performed.
Affinity purification ofBP autoantibodies against the recombinant phage plaques. An agar plate containing Y 1090 Escherichia coli lawns infected with plaque-pure recombinant phages was overlaid with an NC filter soaked in 10 mM IPTG and incubated at 370C for 2 h. The filters were then removed, blocked with 4% BSA in PTX for I h, and incubated with the same BP serum used to screen the library. Nonspecifically bound antibodies were removed by five washes with PTX. Specifically bound BP autoantibodies were eluted from the NC filters using 0.2 M glycine HCI, pH 2.8, and immediately neutralized with 1 M Tris, pH 9.5. The eluted antibodies were dialyzed with Tris-buffered saline (TBS), concentrated by ultrafiltration, and characterized by IF and immunoblotting procedures.
Production of cDNA-encoded BP fusion protein by lysogens. Lambda-gt I Ilysogens were generated in E. coli Y1089 using plaquepurified lambda-BP1 80 phages following procedures described by Earnshaw et al. (17) . Liquid cultures of BP180 lysogens were induced to enter into the lytic phase by raising the temperature to 450C for 15 min followed by a 2-h incubation at 370C in the presence of 10 mM IPTG as described by Miller (18) . A time course study was performed in order to determine the optimal incubation time for the production ofthe BP FP. BP180 lysogens were harvested by centrifugation and the FP extracted and analyzed by SDS-PAGE and immunoblotting as described above.
Immunization ofrabbits with BP180fusion protein. Total extracts of the BP 180 lysogen in 1% SDS were fractionated by SDS-PAGE and electrotransferred to NC paper as described above. A horizontal strip of NC containing the 135-kD BP180 FP was cut out, frozen in liquid nitrogen, and pulverized with a mortar and pestle. The powder was resuspended in TBS, mixed with complete Freund adjuvant, and injected subcutaneously into a rabbit as reported elsewhere (19) . Booster doses were given every 2 wk. The rabbit anti-BP180 FP serum was subsequently used for immunocytochemical and immunoblot procedures.
Subcdoning of the lambda cDNA inserts. Recombinant bacteriophages, lambda-BP240, and lambda-BP1 80 were isolated from largescale liquid lysates of infected LE392 cells, and the phage DNA was extracted according to the procedure ofAusubel et al. (20) . The cDNA inserts were obtained by digestion of the recombinant lambda DNA with Eco RI and were purified by gel electrophoresis using SeaPlaque low melting temperature agarose (FMC Corp., Rockland, ME). The BP240 and BP1 80 cDNA inserts were ligated into the Eco RI site ofthe Bluescript KS' vector (Stratagene Inc., La Jolla, CA) and the resulting constructs will be referred to as pBKS-BP240 and pBKS-BP180, respectively.
Northern blot analysis. Northern analysis was performed as previously described (21) . Total RNA extracted from a primary culture of human keratinocytes was fractionated by formaldehyde/agarose gel electrophoresis (35 gg total RNA/lane) and transferred to NC. The RNA blots were prehybridized at 42°C in a solution of 50% formamide, 20 mM Hepes, pH 7.4, 5X SSC, 1X Denhardt's solution, 10 ug/ml yeast tRNA, and 10 ,ug/ml sonicated, boiled salmon sperm DNA. 32P-labeled cRNA probes were prepared in the following manner. The recombinant plasmids, pBKS-BP240 and pBKS-BP180, were linearized and the appropriate RNA polymerase, T3 or T7, was used to generate a radiolabeled RNA strand complementary to the DNA template strand. The radiolabeled probes were added to the above hybridization solution at 4 X l0 cpm/ml and then hybridized with the fractionated RNA at 42°C overnight. The blots were washed in 0.1X SSC, 0.1% SDS at 70°C, and exposed to Kodak XAR5 film using Lightning Plus intensifying screens (DuPont Co.). In certain cases, as indicated, the radiolabeled RNA blots were treated with 0.1 g/ml RNase A in 2X SSC at room temperature for 15 min, and subsequently washed in 0.1X SSC, 0.1% SDS at 50°C.
Results
Identification ofcDNA clones that encode epitopes recognized by BP autoantibodies. After screening 5 X 105 clones of the human keratinocyte cDNA expression library with the BP serum containing autoantibodies against the BP240 and BP180 antigens, several immunoreactive clones were detected, two ofwhich have been further characterized. BP autoantibodies were affinity purified against the FP of each of these clones and were subsequently analyzed by immunoblot and indirect IF. As shown in Fig. 1, lane 1 , the FP of one clone, lambda-BP240, immunoadsorbed antibodies directed against the BP240 antigen. BP autoantibodies purified against the products of the second cDNA clone, lambda-BP180, specifically recognized the BPl 80 antigen by immunoblot analysis (Fig. 1,  lane 2) . Both of these affinity-purified autoantibody preparations stained the BMZ of human skin by indirect IF and showed no cross-reactivity with other epidermal antigens by immunoblotting.
Restriction enzyme analysis of these clones revealed DNA inserts of 1.6 kb for the lambda-BP240 cDNA and 1.0 kb for the lambda-BPl 80 cDNA.
Northern blot analysis. Radiolabeled, strand-specific cRNA probes generated for both of the BP cDNAs were hybridized with human keratinocyte RNA; the resulting autoradiogram is shown in Fig. 2 . The BP180 cRNA probe, which was prepared using T3 RNA polymerase, was found to hybridize with two bands at 6.0 and 4.9 kb, the smaller band co-migrating with the 28S rRNA band (lane 1). Weak hybridization with a 4.9-kb band was also seen with the BPI 80 probe generated by the T7 RNA polymerase (lane 2). The hybridization with the 4.9-kb band by both of the BP180 probes was selectively eliminated by treatment of the blots with RNase A, suggesting that this observed hybridization was due to short stretches of homology with an abundant RNA species, such as 28S rRNA.
The BP240 cRNA probe generated by T7 RNA polymerase hybridized with a band of -8.5 kb (Fig. 2, lane 4) . The opposite strand showed no hybridization demonstrating the low level of nonspecific hybridization (Fig. 2, lane 3) .
Analysis offusion protein produced by the BP-180 lysogen. Lysogenic Y 1089 E. coli bearing the lambda-BPl 80 prophage produced FP after induction of the lytic phase in the presence of IPTG. As shown in Fig. 3 Fig. 4 . Fig. 4 A shows a set of immunoblots containing a total protein extract from the BPI 80 lysogen labeled with the sera from seven BP patients. A positive reaction with the FP can be seen in all seven lanes. Fig.  4 (Fig. 5 A) . No reactivity with the BP240 antigen was detected on these blots.
This rabbit antiserum also stained the BMZ of human skin in a linear pattern by indirect IF (Fig. 5 B) Fig. 1 , lane 1. Furthermore, this analysis demonstrated that the BP240 epitopes recognized by these affinity-purified autoantibodies are not found on the BP180 antigen. In a similar analysis, clone lambda-BP180 was shown to express a set of epitopes which are present on the BP180 epidermal antigen, but not found on the BP240 antigen. This demonstration that the epitopes present on the BP180 antigen are not merely a subset of BP240 epitopes indicates that the BP180 antigen is not a breakdown product of BP240. Further clarification of the biosynthetic relationship between the two major BP antigens was obtained by the Northern blot analysis which demonstrated that BP240 and BPl 80 antigens are encoded by distinct RNA transcripts. The BP240 cRNA probe hybridized with a single RNA transcript of -8.5 kb, while the BPI 80 probe hybridized with a 6.0-kb transcript from human keratinocytes. No cross-hybridization between these two transcripts was detected. The sizes of these hybridizing transcripts are well within the range ofexpected sizes based on the apparent molecular weights of the BPl 80 and BP240 epidermal polypeptides. It is clear from the above data that the BP240 and BPI 80 antigens do not arise as a posttranslational processing ofa single translation product. A comparison ofthe nucleotide sequence of a portion of the lambda-BP240 cDNA (Giudice, G., P. Elias, and L. Diaz, unpublished data) with the The lambda-BP1 80 cDNA clone was further characterized by analyzing the cDNA-encoded FP using a variety of immunological techniques. In order to produce large amounts ofthis FP, a BPI 80 lysogen was generated by infecting Y 1089 E. coli with the phages from clone lambda-BP1 80. SDS-PAGE and immunoblot analysis of the BPI 80 lysogen extract identified a 135-kD IPTG-inducible FP which reacted strongly with the BP serum that was used to screen the cDNA library. As expected, the BP 180 FP was also recognized on an immunoblot, by a rabbit antibody directed against beta-galactosidase. This confirms that the BPI 80 cDNA was inserted into the lambdagtl 1 vector in such a way that the BPI 80 reading frame was in register with that of the lacZ coding region. The beta-galactosidase portion of such an FP generated by lambda gtl 1 accounts for 114 kD of its total size. Based on an apparent molecular weight of 135 kD for the lambda BP180 FP, the cDNA-encoded portion should correspond to - Fig. 5 A) .
Immunolocalization (3, 5, 6) . The rabbit antiserum was also analyzed by immuno-EM on ultrathin sections of human skin using the indirect immunoperoxidase method. This analysis demonstrated that the immunoreactants were localized to the region of the epidermal hemidesmosome, overlapping the basal cell membrane. As previously reported from our laboratory as well as others, a very similar immuno-EM staining pattern is also produced by human BP sera (5, 7, 8, 22) . The major conclusions which can be drawn from this molecular genetic analysis ofthe major BP antigens are as follows.
The BPl 80 and BP240 antigens are the products of distinct RNA transcripts. The cloned portion ofthe BP1 80 and BP240 antigens do not contain common epitopes, i.e., each ofthe two cDNA-encoded FPs is antigenically distinct by immunoblotting. 44% of BP sera and 88% of HG sera recognized epitopes which are located within the stretch of -200 amino acids encoded by the lambda-BPl 80 cDNA. And finally, the BP1 80 antigen has been localized to the epidermal hemidesmosome.
